Discover how AI chatbots are reshaping weight-loss planning with precision and variety, yet face challenges in balancing macronutrients for optimal health.
FTC review periods end for AbbVie-ImmunoGen $10.1B deal and $4B BMS-RayzeBio buyout
AbbVie moved ahead with its $10.1 billion acquisition of antibody-drug conjugate biotech ImmunoGen, while Bristol Myers Squibb’s big acquisition of radiopharmaceuticals biotech RayzeBio is likely